adc

This January, top news includes glycoengineering, anti-malarial antibodies, and PROTACs.

Proteolysis targeting chimeras (PROTACs) are heterobifunctional molecules designed to degrade specific proteins by recruiting an E3 ubiquitin ligase to the target protein, leading to its ubiquitylation and subsequent degradation by the proteasome. This novel mechanism enables PROTACs to eliminate on

ADCs are reshaping biopharma. Biointron explores how antibody-drug conjugates combine precision targeting with potent payloads to transform therapies.

Microtubule inhibitors power certain ADCs. Biointron highlights how these payloads, combined with antibodies, deliver targeted cancer therapies.

ADCs unite antibody targeting with potent payloads. Biointron explains their mechanisms and importance in advancing cancer therapeutics.

Recently, we have seen exciting developments in the antibody-drug conjugate (ADC) space, from cloud computing to radioisotopes.

ADCs have evolved into powerful cancer drugs. Biointron reviews their history, design improvements, and future directions in targeted therapy.

DAR is key to ADC success. Biointron explains how drug-to-antibody ratios shape potency, safety, and outcomes in cancer therapy.

Antibody-drug conjugates (ADCs) have seen significant developments in regulatory review, with several notable announcements in the past few weeks. Innate Pharma received FDA clearance for its investigational new drug (IND) application for IPH4502, a novel topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4. Nectin-4 is a cell membrane adhesion protein overexpressed in several solid tumors, including urothelial, breast, esophageal, lung, ovarian, and pancreatic cancers, with limited expression in normal tissues.

ADCs and checkpoint inhibitors create synergy in oncology. Biointron explains how combining these modalities improves precision and patient outcomes.

Antibody drug development has revolutionized biomedicine. Biointron highlights stages from discovery to approval that shape antibody-based therapies.

Innovative antibody formats like VHHs, scFvs, and ADCs expand therapeutic options. Biointron explores how these formats drive flexibility and efficacy.

Learn the difference between ADC biosimilars as cost-effective alternatives to reference drugs and ADC isotypes engineered for distinct therapeutic properties in cancer treatment.

ADCs enhance in vivo research precision. Biointron explores how targeted payload delivery improves study accuracy and supports next-generation therapeutic design.

Hepatitis B virus (HBV) infection is a major global health issue, driven by high levels of immunosuppressive viral antigens, the host immune system's failure to effectively control the virus, and the immunosuppressive environment of the liver. Existing therapies have limited effectiveness in eliminating the hepatitis B surface antigen (HBsAg).